172 related articles for article (PubMed ID: 37990682)
1. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.
Richards J; Bang N; Ratliff EL; Paszkowiak MA; Khorgami Z; Khalsa SS; Simmons WK
Obes Pillars; 2023 Sep; 7():100080. PubMed ID: 37990682
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review.
Aoun L; Almardini S; Saliba F; Haddadin F; Mourad O; Jdaidani J; Morcos Z; Al Saidi I; Bou Sanayeh E; Saliba S; Almardini M; Zaidan J
J Clin Transl Endocrinol; 2024 Mar; 35():100333. PubMed ID: 38449772
[TBL] [Abstract][Full Text] [Related]
3. SipNose-topiramate: a potential novel approach to binge eating management.
Kobo-Greenhut A; Zohar-Beja A; Hadar L; Itzhaki L; Karasik A; Caraco Y; Frankenthal H; Shahaf D; Ekstein D; Shichor I; Gur E
J Eat Disord; 2023 Jun; 11(1):102. PubMed ID: 37365668
[TBL] [Abstract][Full Text] [Related]
4. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.
Da Porto A; Casarsa V; Colussi G; Catena C; Cavarape A; Sechi L
Diabetes Metab Syndr; 2020; 14(4):289-292. PubMed ID: 32289741
[TBL] [Abstract][Full Text] [Related]
5. Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa.
Dalai SS; Adler S; Najarian T; Safer DL
Contemp Clin Trials; 2018 Jan; 64():173-178. PubMed ID: 29038069
[TBL] [Abstract][Full Text] [Related]
6. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.
Wang W; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
Mol Psychiatry; 2024 Mar; ():. PubMed ID: 38486046
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients.
Masaki T; Ozeki Y; Yoshida Y; Okamoto M; Miyamoto S; Gotoh K; Shibata H
Metabolites; 2022 Feb; 12(2):. PubMed ID: 35208221
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.
Safer DL; Adler S; Dalai SS; Bentley JP; Toyama H; Pajarito S; Najarian T
Int J Eat Disord; 2020 Feb; 53(2):266-277. PubMed ID: 31721257
[TBL] [Abstract][Full Text] [Related]
9. Overview of the treatment of binge eating disorder.
McElroy SL; Guerdjikova AI; Mori N; Munoz MR; Keck PE
CNS Spectr; 2015 Dec; 20(6):546-56. PubMed ID: 26594849
[TBL] [Abstract][Full Text] [Related]
10. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.
Chuong V; Farokhnia M; Khom S; Pince CL; Elvig SK; Vlkolinsky R; Marchette RC; Koob GF; Roberto M; Vendruscolo LF; Leggio L
JCI Insight; 2023 Jun; 8(12):. PubMed ID: 37192005
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder.
Claudino AM; de Oliveira IR; Appolinario JC; Cordás TA; Duchesne M; Sichieri R; Bacaltchuk J
J Clin Psychiatry; 2007 Sep; 68(9):1324-32. PubMed ID: 17915969
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice.
Amodeo G; Cuomo A; Bolognesi S; Goracci A; Trusso MA; Piccinni A; Neal SM; Baldini I; Federico E; Taddeucci C; Fagiolini A
Expert Opin Pharmacother; 2019 Apr; 20(6):679-690. PubMed ID: 30696303
[TBL] [Abstract][Full Text] [Related]
13. Reevaluating the Binge Eating Scale cut-off using DSM-5 criteria: analysis and replication in preoperative metabolic and bariatric surgery samples.
Jeong H; Hapenciuc G; Meza E; Le JT; Heinberg LJ; Marek RJ
Surg Obes Relat Dis; 2023 Sep; 19(9):945-949. PubMed ID: 36959027
[TBL] [Abstract][Full Text] [Related]
14. Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Guerdjikova AI; Walsh B; Shan K; Halseth AE; Dunayevich E; McElroy SL
Adv Ther; 2017 Oct; 34(10):2307-2315. PubMed ID: 28918581
[TBL] [Abstract][Full Text] [Related]
15. Treatment of binge eating disorder.
Wilson GT
Psychiatr Clin North Am; 2011 Dec; 34(4):773-83. PubMed ID: 22098803
[TBL] [Abstract][Full Text] [Related]
16. Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis.
Brownley KA; Berkman ND; Peat CM; Lohr KN; Cullen KE; Bann CM; Bulik CM
Ann Intern Med; 2016 Sep; 165(6):409-20. PubMed ID: 27367316
[TBL] [Abstract][Full Text] [Related]
17. Treatment of binge-eating disorder with topiramate: a clinical case series.
Shapira NA; Goldsmith TD; McElroy SL
J Clin Psychiatry; 2000 May; 61(5):368-72. PubMed ID: 10847312
[TBL] [Abstract][Full Text] [Related]
18. Combination Phentermine-Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study.
Guerdjikova AI; Williams S; Blom TJ; Mori N; McElroy SL
Innov Clin Neurosci; 2018 Jun; 15(5-6):17-21. PubMed ID: 30013815
[No Abstract] [Full Text] [Related]
19. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton SA; Mosenzon O; Wright EE
Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
